ArticleClinical kidney journal2026
Repeat kidney biopsy in patients with ANCA-associated vasculitis and suspected kidney relapse.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of repeat kidney biopsy in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with suspected renal relapse remains uncertain. Clinical indicators such as hematuria, proteinuria and ANCA reappearance often guide therapy but may not reliably distinguish active vasculitis from chronic damage. Repeat biopsy may also provide prognostic information in patients with prolonged immunosuppressive exposure. Methods: We retrospectively analyzed adults with biopsy-proven AAV who underwent a second kidney biopsy (KB2) for suspected renal relapses. Clinical, laboratory and histopathologic data from the first (KB1) and KB2 were reviewed. Dynamic variations in ANCA, hematuria and proteinuria between 6 months post-KB1 and -KB2 were assessed for their association with histologic activity. Results: Forty patients were included; 25 (62%) had histologically active vasculitis on KB2, whereas 15 (38%) showed inactive lesions. Active disease was associated with the presence ( Conclusion: Clinical and laboratory findings alone often overestimate renal relapses. Dynamic changes in ANCA and hematuria improve prediction but remain insufficient to replace biopsy confirmation, which provides essential diagnostic and prognostic information in relapsing AAV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.